Ellice Wong, MD
Assistant Professor of Medicine (Medical Oncology)DownloadHi-Res Photo
Cards
Appointments
Medical Oncology
Primary
Additional Titles
Director, Newington VA Hematology/Oncology Service, VA CT Healthcare System
Contact Info
Faculty: Medical Oncology-Hematology Program
950 Campbell Ave, 111D
West Haven, CT 06516
United States
Appointments
Medical Oncology
Primary
Additional Titles
Director, Newington VA Hematology/Oncology Service, VA CT Healthcare System
Contact Info
Faculty: Medical Oncology-Hematology Program
950 Campbell Ave, 111D
West Haven, CT 06516
United States
Appointments
Medical Oncology
Primary
Additional Titles
Director, Newington VA Hematology/Oncology Service, VA CT Healthcare System
Contact Info
Faculty: Medical Oncology-Hematology Program
950 Campbell Ave, 111D
West Haven, CT 06516
United States
About
Titles
Assistant Professor of Medicine (Medical Oncology)
Positions outside Yale
Director, Newington VA Hematology/Oncology Service, VA CT Healthcare System
Appointments
Medical Oncology
Assistant ProfessorPrimary
Other Departments & Organizations
- Internal Medicine
- Medical Oncology
- Yale Ventures
Education & Training
- Residency
- New York University Medical Center (2007)
- MD
- New York Medical College (2004)
- BS
- Yale University, Molecular Biophysics & Biochemistry (2000)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Ellice Wong's published research.
Publications Timeline
A big-picture view of Ellice Wong's research output by year.
Michal Rose, MD
Natalia Neparidze, MD
Amy Justice, MD, PhD
Michael Cecchini, MD
Patrick Gallagher, MD, BS
Roxanne Wadia, MD
12Publications
21Citations
Publications
2023
MDS Chapter
Wong EY, Rose MG. Update on MDS for Cancer: Principles & Practice of Oncology, 12th edition, 2023.Commentaries, Editorials and LettersCML Chapter
Wong EY, Rose MG. Update on CML for Cancer: Principles & Practice of Oncology, 12th edition, 2023.Commentaries, Editorials and LettersCLL Chapter
Wong EY, Rose MG. Update on CLL for Cancer: Principles & Practice of Oncology, 12th edition, 2023.Commentaries, Editorials and Letters
2020
Disorders of Red Blood Cells
Wong E, Rose MG, Berliner N. Disorders of red blood cells. In: Wing E. and Shiffman F. eds. Cesil Essentials of Medicine, 10th ed. Elsevier 2020.ChaptersClinical Disorders of Granulocytes and Monocytes
Wong E, Rose MG and Berliner N. Clinical Disorders of Granulocytes and Monocytes. In: Wing E. and Schiffman F. eds. Cecil Essentials of Medicine, 10th ed. Elsevier 2020.Chapters
2019
Multicenter phase II trial of RRx-001 in previously treated SCLC.
Morgensztern D, Rose M, Morris J, Ma P, Brzezniak C, Zeman K, Padmanabhan A, Hirth J, Spira A, Wong E, Padda S, Waqar S. Multicenter phase II trial of RRx-001 in previously treated SCLC. Journal Of Clinical Oncology 2019, 37: e20104-e20104. DOI: 10.1200/jco.2019.37.15_suppl.e20104.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerRRx-001Partial responseStable diseaseOverall survivalPrior linesCommon treatment-emergent adverse eventsSingle-arm phase II studyArm phase II studyMulticenter phase II trialTreatment-emergent adverse eventsPhase II studyPhase II trialPlatinum-resistant diseaseCell lung cancerOverall response rateTreat populationII trialPrimary endpointAdverse eventsEtoposide chemotherapyII studyComplete responsePlatinum therapyLung cancer
2018
Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma
Giri S, Wong E, Rose M, Wadia R, Park L, Justice A, Neparidze N. Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma. Blood 2018, 132: 3162. DOI: 10.1182/blood-2018-99-115633.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyMultiple myelomaEM diseaseUninfected patientsClinical characteristicsLytic lesionsOutcome of MMRisk of MMImpact of HAARTRole of HAARTStage 3 diseaseSymptomatic multiple myelomaTime of diagnosisAggressive clinical courseAging Cohort StudyClinical outcome dataCourse of diseasePlasma cell disordersDurie-Salmon stageVeterans Health AdministrationImpact of HIVSignificant differencesStage 1High rateStage 2Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study)
Zwicker J, Schlechter B, Stopa J, Liebman H, Aggarwal A, Caughey T, Bauer K, Kuemmerle N, Wong E, Wun T, Mclaughlin M, Puligandla M, Neuberg D, Furie B, Flaumenhaft R. Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study). Blood 2018, 132: 985. DOI: 10.1182/blood-2018-99-114946.Peer-Reviewed Original ResearchCitationsAltmetricConceptsVenous thromboembolismDay 56Major hemorrhageAdvanced cancerAntithrombotic efficacyCancer patientsHigh riskThrombus formationD-dimer plasma concentrationIncidence of VTEPlasma D-dimer levelsNon-small cell lungPhase II clinical trialPlatelet-dependent thrombin generationPrevent Venous ThromboembolismPhase II studySecond-line chemotherapySymptomatic pulmonary embolismD-dimer levelsLower extremity DVTPhase II trialMonths of initiationLower extremity ultrasoundSoluble P-selectinInitial human studiesQUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer.
Padda S, Brzezniak C, Waqar S, Wakelee H, Ma P, Rose M, Reid T, Spira A, Wong E, Zeman K, Oronsky B, Abrouk N, Morgensztern D. QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer. Journal Of Clinical Oncology 2018, 36: e20575-e20575. DOI: 10.1200/jco.2018.36.15_suppl.e20575.Peer-Reviewed Original ResearchCitations
2014
Electronic Hematology Consultations at Veterans Affairs (VA) Connecticut: Analysis of Effects on Patient Care, and Provider and Patient Satisfaction
Neparidze N, Cecchini M, Wong E, Rose M. Electronic Hematology Consultations at Veterans Affairs (VA) Connecticut: Analysis of Effects on Patient Care, and Provider and Patient Satisfaction. Blood 2014, 124: 4857. DOI: 10.1182/blood.v124.21.4857.4857.Peer-Reviewed Original ResearchConceptsElectronic medical recordsHematology consultationTimeliness of careE-consultsFace visitsHematology clinicPatient satisfactionProvider satisfactionPatient careAbnormal coagulation profileMajority of patientsComprehensive electronic medical recordsPeripheral blood smearUnnecessary patient visitsNumber of veteransHealthcare delivery methodsVenous thromboembolismMedical chartsCoagulation profileRetrospective reviewAddition patientsPatient preferencesMedical recordsPatient visitsIron indices
Academic Achievements & Community Involvement
activity LCME Education Subcommittee, Yale School of Medicine
CommitteesMemberDetails2022 - Presentactivity American Society of Hematology
Professional OrganizationsMemberDetails2008 - Presentactivity VA CT Healthcare System Cancer Committee
CommitteesMemberDetails2008 - Presentactivity VA CT Healthcare System Blood Utilization Committee
CommitteesCo-ChairDetails2014 - Presentactivity VA CT Healthcare System COVID-19 Treatment Committee
CommitteesMemberDetails2020 - Present
News
News
Get In Touch
Contacts
Email
Mailing Address
Faculty: Medical Oncology-Hematology Program
950 Campbell Ave, 111D
West Haven, CT 06516
United States